Your session is about to expire
← Back to Search
RSV/hMPV mRNA / LNP 2 Group 4 for Metapneumovirus Infection
Study Summary
This trial aims to test a new vaccine to prevent lower respiratory tract diseases caused by respiratory syncytial virus and human metapneumovirus in older adults. Participants will receive one injection of the
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are numerous medical facilities conducting this study within the local area?
"Patients are being recruited at Investigational Site 0360004 in Sydney, New york; Meridian Clinical Research Site 8400007 in Binghamton, Louisiana; and Velocity Clinical Research Site 8400016 in Metairie, California among an additional 17 undisclosed locations."
Is the enrollment for participants currently open in this medical study?
"As per clinicaltrials.gov, this investigation is presently enlisting participants. The trial was initially listed on January 23rd, 2024, and the latest update was made on March 7th, 2024."
What is the overall patient enrollment count for this particular research investigation?
"Affirmative. Details listed on clinicaltrials.gov signify that this investigation is actively seeking participants. The initial posting date of the trial was 23rd January 2024, with the most recent update noted to be on 7th March 2024. A total of 545 patients are being sought across seventeen different locations for inclusion in this study."
What are the risks associated with RSV/hMPV mRNA / LNP 1 Group 7 in terms of patient safety?
"Our group at Power rates the safety of RSV/hMPV mRNA / LNP 1 Group 7 as a level 1 on our scale due to being in Phase 1, indicating minimal existing data supporting both safety and effectiveness."
What is the primary objective of this research endeavor?
"The primary objective of this study, to be assessed on Day 1 and Day 29, is the identification of abnormal results in biological tests. Secondary endpoints involve assessing RSV B serum nAb levels before vaccination (D01), at 28 days (D29), after 3 months (D91), and following 6 months (D181) post-vaccination using the monovalent RSV formulation. This includes evaluating pre-vaccination, day 28, month 3, and month 6 RSV A serum anti-F IgG antibody titers with the same vaccine formulation as well as hMPV A serum"
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger